Sequencing of cabazitaxel and abiraterone acetate following docetaxel in metastatic castration-resistant prostate cancer (mCRPC)

被引：2
|
作者：
Schnadig, Ian D.
Bhor, Menaka
Vogelzang, Nicholas J.
Hennessy, Daniel
Nicacio, Leonardo V.
Berry, William R.
Hutson, Thomas E.
Fleming, Mark T.
Cowey, C. Lance
Saravanan, Shanmugapriya
Dhanda, Rahul
Sonpavde, Guru
机构：
[1] McKessson Specialty Hlth, Compass Oncol, Tualatin, OR USA
[2] McKesson Special Hlth, The Woodlands, TX USA
[3] US Oncol Network, The Woodlands, TX USA
[4] Comprehens Canc Ctr Nevada, Las Vegas, NV USA
[5] Sanofi, Medfield, MA USA
[6] Sanofi, Bridgewater, NJ USA
[7] US Oncol, Canc Ctr North Carolina, Raleigh, NC USA
[8] Texas Oncol Baylor Charles A Sammons Canc Ctr, Dallas, TX USA
[9] Virginia Oncol Associates, Norfolk, VA USA
[10] Texas Oncol PA, Baylor Charles A Sammons Canc Ctr, Dallas, TX USA
[11] Univ Alabama Birmingham, Ctr Comprehens Canc, Birmingham, AL 35294 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 06期
关键词：
D O I：
10.1200/jco.2013.31.6_suppl.79
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
79
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Optimal sequencing of docetaxel and abiraterone in men with metastatic castration-resistant prostate cancer (mCRPC).
    Maughan, Benjamin Louis
    Suzman, Daniel L.
    Nadal, Rosa
    Bassi, Sunakshi
    Schweizer, Michael Thomas
    Antonarakis, Emmanuel S.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (07)
  • [2] Outcomes with different sequences of cabazitaxel and abiraterone acetate following dooetaxel in metastatic castration-resistant prostate cancer (mCRPC)
    Sonpavde, G.
    Bhor, M.
    Hennessy, D.
    Bhowmik, D.
    Shen, L.
    Nicacio, L.
    Rembert, D.
    Yap, M.
    Dhanda, R.
    Schnadig, I.
    [J]. EUROPEAN JOURNAL OF CANCER, 2013, 49 : S698 - S698
  • [3] Activity of cabazitaxel following docetaxel and abiraterone acetate in patients with castration-resistant prostate cancer
    Sella, Avishay
    Sella, Tal
    Peer, Avivit
    Berger, Raanan
    Frank, Stephen Jay
    Gez, Eli
    Sharid, David
    Hayat, Henry
    Hanovich, Ekaterina
    Kovel, Svetlana
    Rosenbaum, Eli
    Neiman, Victoria
    Keizman, Daniel
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (06)
  • [4] Activity of cabazitaxel following docetaxel and abiraterone acetate in patients with castration-resistant prostate cancer.
    Sella, Avishay
    Sella, Tal
    Peer, Avivit
    Berger, Raanan
    Frank, Stephen Jay
    Gez, Eliahu
    Sharid, David
    Hayat, Henry
    Rosenbaum, Eli
    Neiman, Victoria
    Keizman, Daniel
    Kovel, Svetlana
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [5] Abiraterone acetate (AA) with or without cabazitaxel (CBZ) in treatment of chemotherapy naive metastatic castration-resistant prostate cancer (mCRPC)
    Slovin, Susan F.
    Knudsen, Karen E.
    Halabi, Susan
    Fleming, Mark T.
    Molina, Ana M.
    Wolf, Steven Paul
    de Leeuw, Renee
    Fernandez, Celina
    Kang, Praneet
    Southwell, Traci
    Jones, Carol L.
    Fernandez, Escarleth
    Kelly, William Kevin
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [6] Activity of Cabazitaxel After Docetaxel and Abiraterone Acetate Therapy in Patients With Castration-Resistant Prostate Cancer
    Sella, Avishay
    Sella, Tal
    Peer, Avivit
    Berger, Raanan
    Frank, Stephen Jay
    Gez, Eli
    Sharide, David
    Hayat, Henry
    Hanovich, Ekaterina
    Kovel, Svetlana
    Rosenbaum, Eli
    Neiman, Victoria
    Keizman, Daniel
    [J]. CLINICAL GENITOURINARY CANCER, 2014, 12 (06) : 428 - 432
  • [7] Optimal Sequencing of Docetaxel and Abiraterone in Men With Metastatic Castration-Resistant Prostate Cancer
    Maughan, Benjamin L.
    Xhou, Xian C.
    Suzman, Daniel L.
    Nadal, Rosa
    Bassi, Sunakshi
    Schweizer, Michael T.
    Antonarakis, Emmanuel S.
    [J]. PROSTATE, 2015, 75 (15): : 1814 - 1820
  • [8] Phase I/II trial of cabazitaxel plus abiraterone in patients with metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel and abiraterone
    Massard, C.
    Mateo, J.
    Loriot, Y.
    Pezaro, C.
    Albiges, L.
    Mehra, N.
    Varga, A.
    Bianchini, D.
    Ryan, C. J.
    Petrylak, D. P.
    Attard, G.
    Shen, L.
    Fizazi, K.
    de Bono, J.
    [J]. ANNALS OF ONCOLOGY, 2017, 28 (01) : 90 - 95
  • [9] Response to cabazitaxel in patients with metastatic castration-resistant prostate cancer (mCRPC) poorly responding to docetaxel
    Angelergues, A.
    Bellmunt, J.
    Efstathiou, E.
    Gonzalez, I.
    Gyftaki, R.
    Delanoy, N.
    Ozguroglu, M.
    Flechon, A.
    Guillot, A.
    Le Moulec, S.
    Castellano, D.
    Esteban, E.
    Munarriz, J.
    Campos Balea, B.
    Ardavanis, A.
    Stefanou, D.
    Oudard, S.
    [J]. EUROPEAN JOURNAL OF CANCER, 2015, 51 : S488 - S488
  • [10] Optimal sequencing of docetaxel and abiraterone in men with metastatic castration-resistant prostate cancer (mCRPC): Effect of early docetaxel on outcomes.
    Maughan, Benjamin Louis
    Suzman, Daniel L.
    Nadal, Rosa
    Bassi, Sunakshi
    Schweizer, Michael Thomas
    Antonarakis, Emmanuel S.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
12345